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cell membrane phospholipids. Choline 
is metabolized through phosphoryla-
tion that produces phosphorylcholine 
through choline kinase, further incor-
porated into phosphatidylcholine, a 
major component of biological mem-
branes and a member of the lecithin 
group of yellow-brownish fatty sub-
stances. Choline is also metabolized 
through acetylation through choline 
acetyltransferase, which produce ace-
tylcholine.5 Thus PET/CT imaging with 
11C-choline and 18F-fluorocholine can 
be used to identify tumoral tissue where 
an increase in cell proliferation as well 
as the activity of the enzyme choline is 
associated with an increase in choline 
component and has long been used in 
work up of prostate cancer.
Apart from prostatic adenocar-
cinoma, 18F-choline PET/CT is known 
to have good performances in other 
neoplastic cell type, such as hepatocel-
lular-carcinoma, glioma, bone tumor, 
soft-tissue tumor, and lung cancer.6 
Besides, 18F-choline PET/CT can be use-
ful in detecting hyperplastic tissue, such 
as thymomas and parathyroid adenoma.6–8
But for lung cancer, even for 
bronchioloalveolar cancer subtype, 
although 18F-choline PET/CT is a reli-
able tool for lung tumor staging and to 
differentiate malignant and benign lung 
lesions (through the phosphorylation and 
acetylation pathways5), a superiority of 
18F-choline over FDG has not been dem-
onstrated in this setting, except for the 
detection of brain metastases,6,9,10 whereas 
its price is three to five times the price of 
FDG. 18F-choline PET/CT imaging, like 
18F-FDG PET/CT scan, is also subject to 
several causes of false-positive, such as 
infection, tuberculoma, or inflammation.11
There is only one published case of 
mucinous cancer detected with 18F-choline 
PET/CT. It was a primary poorly differen-
tiated mucinous rectal cancer.12 So in the 
case of the mucinous colorectal adenocar-
cinoma lung metastasis reported by Balata 
et al.; whether 18F-choline PET/CT could 
have significantly contributed to diagnosis 
remains uncertain.
The differentiation degree could 
play a role in the avidity of tumor cell 
for 18F-choline. The spatial resolution of 
18F-choline PET/CT (from 4 to 8 mm) 
being similar to that of 18F-FDG PET/
CT, the positivity of 18F-choline PET/CT 
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In Response:
Balata et al. elegantly reported the 
case of an 84-year-old female with a sol-
itary endobronchial mucinous colorec-
tal adenocarcinoma metastasis. The 
computed tomography (CT) imaging 
was initially consistent with a broncho-
cele, whereas 18F-Flurodeoxyglucose 
(18F-FDG) positron emission tomogra-
phy (PET)/CT imaging did not show 
any pathological FDG uptake within the 
lesion. The authors wondered whether 
18F-choline PET/CT could have added 
value to the assessment of possible 
mucinous tumors and raised a more 
general question of the potential role of 
18F-choline PET/CT scan in the man-
agement of lung cancer.
It can be challenging to diag-
nose lung mucinous tumors as a neo-
plasia when using CT scan because 
it often shows bland radiologic find-
ings, such as a well-defined margin 
or absence of enhancement.1 Besides, 
mucinous tumor is a well-known fac-
tor of false-negative 18F-FDG PET/
CT scan.1–3 In this clinical setting, 18F-
FDG PET/CT might show only low 
FDG uptake within the lesion, hence 
the tumor has low tumor cellular-
ity and abundant mucin content. FDG 
uptake may depend on the thickness of 
the solid portion of invasive carcinoma 
in the wall of the lesion.1,4 Therefore, 
18F-FDG PET/CT may not be sensitive 
enough to exclude the possibility of 
malignancy, such as mucinous adeno-
carcinoma, especially in tumors with-
out visible thick, and enhancing walls.
Choline is a quaternary ammo-
nium base, which is a precursor of 
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probably depends mainly on the thickness 
of the solid portion of tumoral lesion.
Thus in a previously reported case 
of ovarian mucinous cystadenocarcinoma, 
both 11C-choline PET and 18F-FDG PET 
showed a large cold area and small hot 
areas in the primary tumor, corresponding 
to, respectively, the large cystic lesion and 
small solid tumors containing adenocarci-
noma cells in surgical histology.4
In conclusion, the question of 
whether 18F-choline PET/CT has good 
performances for mucinous tumors 
detection remains open and further 
studies are needed.
Although this technique may pro-
vide some valuable metabolic informa-
tion, the association of an accessible 
“bronchocele like” lesion with a history of 
cancer should encourage to perform biop-
sies, as suggested by both of our observa-
tions (i.e., prostatic adenocarcinoma lung 
metastasis13 and endobronchial mucinous 
colorectal adenocarcinoma metastasis).
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mutations. In this letter, we would like to 
share our experience of a case with a non-
conservative double amino acid change 
that has not been described before. 
A 76-year-old never-smoker woman in 
good clinical conditions was referred 
to our Institution for a solid lesion in 
the left lung. Subsequent procedures, 
including positron emission tomog-
raphy scan and fibrobronchoscopy, 
revealed a lung adenocarcinoma, con-
firmed by TTF-1 and CK7 immuno-
histochemistry positivity, apparently 
limited to the left upper lobe; therefore, 
the patient underwent radical left upper 
lobectomy. The surgical report revealed 
metastases in mediastinal lymph nodes 
and in the parietal pleura; the final 
stadiation was pT2b (G2), pN2, and 
pM1a for pleural involvement (stage 
IV). Consequently, we considered the 
patient eligible for systemic treatment. 
Sanger sequencing analysis revealed 
four consecutive genetic variants (GAA 
> GTT and TTA > CCA) in the exon 
19 of EGFR, resulting in double amino 
acid substitution: E746V and L747P, 
respectively.
Despite limited and partially 
discordant literature data available 
on these variants,1–3 we considered 
the patient eligible for treatment 
with gefitinib (250 mg/day), started 
in October 2013. Baseline computed 
tomography scan showed pleural effu-
sion and sub-centimetric lesions in the 
lower left lobe; during treatment, no 
radiological response was observed 
(Fig. 1). In May 2014, progressive dis-
ease was defined because of increase 
of left pleural effusion and appear-
ance of new mediastinal and left axil-
lar lymphadenopathies and pulmonary 
lesions. As clinical conditions wors-
ened, further treatments were limited 
to best supportive care until death, 
occurred in October 2014.
The poor outcome of the patient 
encouraged further investigations of 
this case: next generation sequencing 
did not disclose additional mutations, 
confirming our previous data on EGFR 
(Fig. 2A), and analysis in normal DNA 
pointed out the somatic origin of the 
variants.
Sanger sequencing of cDNA 
reported the transcription of these 
four mutations in approximately 50% 
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of tumor cells (Fig. 2B), whereas pro-
tein analysis on tumor tissue revealed 
a marked phosphorylation of EGFR 
when compared with the correspondent 
normal tissue, confirming the activat-
ing role of this double amino acid sub-
stitution (Fig. 2C). Three-dimensional 
structure analysis of our mutated 
EGFR model revealed a rotation of 
approximately 32-degree of Helix A 
(K730-V745), mimicking the EGFR 
structure resulting from T790M-L858R 
mutations, which is characterized by a 
restored ATP affinity and gefitinib resis-
tance.4 This rotation determines a cleft 
allowing the protein to simultaneously 
bind one molecule of gefitinib and one 
molecule of ATP, in a favorable position 
to successfully undergo hydrolysis, as 
also demonstrated by our docking sim-
ulation (Fig. 3).
DISCUSSION
Here, we report the case of a patient 
affected by advanced lung adenocarci-
noma harboring four novel consecutive 
missense mutations in the exon 19 of 
the EGFR gene that result in noncon-
servative double amino acid change 
(E746V-L747P).
Although tyrosine kinase inhibi-
tors (TKIs) are generally recommended 
in EGFR-mutant lung adenocarcinoma, 
to date relatively little is known con-
cerning the EGFR activation status 
related to rare mutations and their sen-
sitivity to TKI.1–3,5
Our data confirmed the somatic 
origin of E746V-L747P genetic vari-
ants and their activating role on EGFR; 
structure prediction revealed a dra-
matic rearrangement of the N-terminal 
lobe of EGFR tyrosine kinase domain 
allowing ATP binding, irrespective of 
gefitinib. Indeed, docking simulations 
pointed out the high affinity of ATP to 
the double mutant in a position highly 
favorable for hydrolysis, resulting in 
TKI resistance.
The activating role of E746V-L747P 
mutations resulting in aberrant rearrange-
ment of the EGFR structure, strongly 
supported by our data, confers weak TKI 
sensitivity and treatment failure.
This case highlights the impor-
tance of EGFR uncommon mutations 
on protein structure as a putative pre-
dictor of TKI efficacy.
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To the Editor:
Recently, we read with interest 
the article by van der Wekken et al.1 
regarding the role of uncommon EGFR 
